Objective: To investigate the effects of recombinant human growth hormone (rhGH) on growth of human gastric cancer cell line in vitro. Methods: Cells were divided into control group, rhGH group, oxaliplatin (L-OHP) group and rhGH+L-OHP group. Cell inhibitory rate, cell cycle and DNA inhibitory rate of human gastric cancer line SGC-7901, at different concentrations of rhGH treatment were detected by cell culture, MTT assay and flow cytometry. Results: There was not distinctly accelerated effect of rhGH on multiplication of SGC-7901 cell line in vitro. There was no statistical significance between rhGH group and control group, or between rhGH+L-OHP group and L-OHP group (P>0.05). Cell inhibitory rate and cell arrested in G0-G1 phase increased. Meanwhile, cells in S phase distinctly decreased and DNA inhibitory rate increased in rhGH+L-OHP group in comparison with L-OHP group (P< 0.01). Conclusion: rhGH does not accelerate the multiplication of human gastric cancer cells. It may increase the therapeutic efficacy when used in combination with anticancer drugs.%目的:通过体外实验,研究重组人类生长激素对胃癌细胞的增殖的影响.方法:实验分为空白组,重组人类生长激素组,奥沙利铂组和重组人类生长激素+奥沙利铂组.用不同浓度的重组人类生长激素处理SGC-7901细胞,采用MTT法和流式细胞仪检测人胃癌细胞株的细胞抑制率,细胞周期和DNA抑制率.结果:体外实验结果表明,重组人类生长激素对SGC-7901细胞株增殖没有明显的促进作用,重组人类生长激素组和空白组以及重组人类生长激素+奥沙利铂组和奥沙利铂组之间没有统计显著性(P＞0.05),细胞抑制率和停止生长的细胞在G0-GI期明显增加(P＜0.01),同时重组人类生长激素+奥沙利铂组和空白组以及奥沙利铂组在S期,细胞数依次下降,DNA抑制率依次增加.重组人类生长激素+奥沙利铂组与奥沙利铂组相比,细胞抑制率有明显上升趋势.结论:体外实验表明,重组人类生长激素并不加快人类胃癌细胞的增殖,与抗癌药物一同使用时,有增加治疗功效的作用.
展开▼
